Use of hemospray for non-variceal esophageal bleeding in an infant  by Paganelli, Massimiliano et al.
Fig. 1. Upper
varices with r
from the ulce
Letters to the Editor
712
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in an infantTo the Editor:
Hemospray (Cook Medical Inc, Bloomington, IN, USA) is a new
device licensed in Canada and Europe for endoscopic hemos-
tasis of non-variceal upper gastrointestinal bleeding. It con-
sists in a hemostatic powder that is sprayed onto actively
bleeding lesions through an application catheter positioned
through the working channel of the endoscope. Such a pow-
der absorbs water almost instantly to form a mechanical bar-
rier that stops the bleeding. In a case series recently
published in the Journal of Hepatology, hemospray was showngastrointestinal endoscopy images of the case described. Upper gastroin
ed wales and spots. A large actively bleeding esophageal ulcer was visuali
r (C). The healing of the ulcer was noted 6 days from the procedure (D).
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der CC BY-NC-ND license.effective in controlling bleeding from portal hypertensive gas-
tropathy [1]. Its efﬁcacy has been previously reported for
bleeding from esophageal, gastric and duodenal ulcers, gastric
varices, and gastric antral vascular ectasia [2–4]. In the largest
series described so far, hemostasis was achieved in 85% of
patients treated with hemospray alone, with 15% of rebleed
rate at 7 days [5]. The use of hemospray in children has not
been reported yet. We describe here the successful use of this
novel device to treat an upper gastrointestinal bleeding in an
11-month old infant.testinal endoscopy performed in the patient at diagnosis (A) shows grade II and III
zed 11 days post-sclerotherapy (B). Hemospray allowed to stop the active bleeding
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Case description
A girl of 10 months of age was referred with clinical and bio-
chemical features of severe cholestasis, mild liver failure, and
severe portal hypertension, and was diagnosed with cirrhosis
secondary to neonatal sclerosing cholangitis. The ﬁrst upper gas-
trointestinal endoscopy performed at diagnosis showed grade II
and III esophageal varices with red wales and spots (Fig. 1A).
No primary prophylaxis was performed because of the lack of
deﬁnite evidence of its effectiveness in children and of the severe
growth failure of the patient (5.8 kg, Z-score <3 standard devi-
ations), which did not allow passing an endoscopic banding
device across the cricopharynx. After 8 weeks from the ﬁrst
endoscopy the patient was admitted for an upper gastrointestinal
bleeding episode. One actively bleeding esophageal varix was
visualized at endoscopy and the bleeding was partially stopped
by two injections of 3 ml of sclerosing agent. After 3 days, a sec-
ond session of sclerotherapy was required to completely control
the bleeding. As her conditions worsened rapidly, the patient
was listed for liver transplantation (LT) with a PELD score of 16
[6]. After 11 days from variceal sclerosis, a severe rebleeding
was observed despite prophylactic intravenous octreotide and
pantoprazole administration. A large actively bleeding post-
sclerotherapy esophageal ulcer was visualized (Fig. 1B). We used
hemospray, which solidiﬁed instantly on the ulcer and stopped
the bleeding (Fig. 1C). No hemorrhagic episode was observed in
the following weeks, and the healing of the ulcer was noted
6 days after the procedure (Fig. 1D). The girl underwent success-
ful LT at the age of 13 months with a reduced liver graft (seg-
ments II–III) and she is well at 2-month follow-up.
Discussion
Upper gastrointestinal bleeding by the age of 5 years is observed
in 60% and 100% of young children with medium and large esoph-
ageal varices, respectively [7]. Children with biliary atresia were
shown to experience the ﬁrst hemorrhagic episode at a median
age of 14 months [8]. Although randomized controlled trials are
lacking, recent evidence showed that primary prophylaxis with
endoscopic banding or sclerotherapy is effective in preventing
bleeding [8]. Nevertheless, the rebleeding rate is higher with scle-
rotherapy than with banding [9]. Unfortunately, in infants and
children weighting less than 8–10 kg the introduction of the
banding device in the esophagus is often impossible, and sclero-
therapy is the only available treatment [8]. Treatment options in
case of rebleeding from sclerotherapy-induced esophageal ulcers
are limited in adults (transjugular intrahepatic portosystemic
shunt, surgical shunts, self-expanding stents, esophageal transec-
tion, Sengstaken–Blakemore tube) and almost absent in young
children, for whom urgent liver transplantation is the only
option. Hemospray has proven effective in adults and we show
here that it could be effective and safe in children as well. Its ease
of use constitutes a further advantage for pediatric gastroenterol-
ogists who are less frequently confronted to upper gastrointesti-
nal bleeding than their colleagues caring for adults. Although
only a temporary mechanical barrier, the solidiﬁed powder
allows to stop the bleeding, and to reduce the immediate need
for invasive and riskful procedures in adults and, hopefully, also
in children [5]. Our preliminary experience described above, if
conﬁrmed, suggests a promising role for hemospray for non-
variceal upper gastrointestinal bleeding in infants and children.
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